<DOC>
	<DOCNO>NCT00036647</DOCNO>
	<brief_summary>The purpose study determine OSI-774 improve overall survival patient incurable stage IIIB/IV non-small cell lung cancer compare standard care . OSI-774 new type drug evaluation call epidermal growth factor receptor ( EGFR ) . OSI-774 investigational drug yet approve U.S. Food Drug Administration ( FDA ) .</brief_summary>
	<brief_title>OSI-774 ( Tarceva ) Treating Patients With Stage III Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Clinical diagnosis stage IIIB IV nonsmall cell lung cancer . Must evidence disease ( clinical radiological ) . Have fail 1 2 prior chemotherapy regimen , recover side effect chemotherapy least 21 day . If patient surgery , surgery least 2 week ago . Patients whose cancer spread brain central nervous system eligible , provide stable dose steroid least 4 week free symptom . If patient receive radiation therapy , treatment least 4 week ago .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Tarceva</keyword>
	<keyword>EGFR</keyword>
	<keyword>erlotinib</keyword>
</DOC>